Endomicroscopy and Crohn´s Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01102855|
Recruitment Status : Completed
First Posted : April 13, 2010
Last Update Posted : August 11, 2011
The main objective of this study is to determine endomicroscopic features of Crohn´s disease.
Crohn´s disease is an inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from anus to mouth, causing a wide variety of symptoms. Diagnosis is based on several histologic features including transmural pattern of inflammation, crypt abscesses and granulomas. Confocal laser endomicroscopy (CLE) is rapidly emerging as a valuable tool for gastrointestinal endoscopic imaging, enabling the endoscopist to obtain an "optical biopsy" of the gastrointestinal mucosa during the endoscopic procedure.
In patients with Crohn´s disease.
|Condition or disease|
Patients underwent colonoscopy for the evaluation of Crohn´s disease. During the endoscopic procedure CLE will be performed.
The patient underwent colonoscopy. During the procedure the patient will receive intravenous fluorescein or topical mucosal staining with acriflavin or cresyl violet, followed by in-vivo CLE of the tissue. Confocal images are digitally saved and analyzed afterwards.
|Study Type :||Observational|
|Estimated Enrollment :||40 participants|
|Official Title:||Confocal Laser Endomicroscopy in Patients With Crohn´s Disease|
|Study Start Date :||October 2009|
|Actual Primary Completion Date :||August 2011|
|Actual Study Completion Date :||August 2011|
- To determine endomicroscopic features of Crohn´s disease. [ Time Frame: October 2009 until May 2010 ]
- Comparison of CLE findings with conventional histology. [ Time Frame: October 2009 until May 2010 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01102855
|Department of Medicine I, University of Erlangen-Nuremberg|
|Erlangen, Germany, 91054|
|Study Director:||Markus F. Neurath||University of Erlangen-Nürnberg|